US Patent

US10039779 — Combination formulation of two antiviral compounds

Method of Use · Assigned to Gilead Pharmasset LLC · Expires 2034-01-30 · 8y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a pharmaceutical composition containing an amorphous form of ledipasvir and a crystalline form of sofosbuvir.

USPTO Abstract

Disclosed are pharmaceutical compositions having an effective amount of substantially amorphous ledipasvir and an effective amount of substantially crystalline sofosbuvir.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2369`	—
`U-1470`	—

Patent Metadata

Patent number: US10039779
Jurisdiction: US
Classification: Method of Use
Expires: 2034-01-30
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Gilead Pharmasset LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.